Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLEY WILSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1932398757
CMS profile
224261
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,820.04

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,771.20 72
Education $48.84 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLEY WILSON

NPI 1932398757 · CMS profile ID 224261

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1932398757?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $1,820.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Neos Therapeutics, LP $20.5312/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984561029 CMS
Corium, LLC $26.8712/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978588565 CMS
ITI, Inc. $23.0412/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040750615 CMS
Otsuka America Pharmaceutical, Inc. $19.8012/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014930907 CMS
Noven Therapeutics, LLC $13.9412/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028339725 CMS
Noven Therapeutics, LLC $24.6511/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028339687 CMS
Otsuka America Pharmaceutical, Inc. $21.0411/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014930899 CMS
Otsuka America Pharmaceutical, Inc. $6.4111/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014930891 CMS
AbbVie Inc. $23.8711/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999782315 CMS
ITI, Inc. $25.5711/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040750609 CMS
Neurocrine Biosciences, Inc. $20.9911/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052249681 CMS
Janssen Pharmaceuticals, Inc $30.1610/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988090905 CMS
Tris Pharma Inc $14.1210/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059382833 CMS
ITI, Inc. $24.7210/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040750593 CMS
ITI, Inc. $48.8410/23/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040750599 CMS
Noven Therapeutics, LLC $12.1510/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028339677 CMS
Alkermes, Inc. $8.0009/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946263 CMS
Otsuka America Pharmaceutical, Inc. $24.2709/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014930883 CMS
Neurocrine Biosciences, Inc. $21.9609/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052249677 CMS
Noven Therapeutics, LLC $20.6009/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028339667 CMS
Alkermes, Inc. $18.3309/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946261 CMS
Tris Pharma Inc $21.4509/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059382803 CMS
Corium, LLC $19.5008/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978405985 CMS
Otsuka America Pharmaceutical, Inc. $19.5808/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014930875 CMS
Bausch Health US, LLC $24.7108/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046946933 CMS
AbbVie Inc. $26.7408/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999782305 CMS
Alkermes, Inc. $28.9808/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946259 CMS
Almatica Pharma LLC $23.1107/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993455575 CMS
Corium, LLC $17.5007/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978549955 CMS
ITI, Inc. $20.1107/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040750584 CMS
Alkermes, Inc. $27.7307/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946257 CMS
Noven Therapeutics, LLC $21.2807/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028339715 CMS
Neos Therapeutics, LP $18.1407/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984533481 CMS
Alkermes, Inc. $12.0907/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946255 CMS
Ironshore Pharmaceuticals Inc. $18.8206/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060465481 CMS
Corium, LLC $22.2206/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978549951 CMS
Lundbeck LLC $14.2306/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032407829 CMS
Alkermes, Inc. $26.4506/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946253 CMS
ITI, Inc. $23.3506/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040750579 CMS
Noven Therapeutics, LLC $23.8206/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028339657 CMS
Neos Therapeutics, LP $14.7906/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984529731 CMS
Janssen Pharmaceuticals, Inc $23.6106/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988090925 CMS
Alkermes, Inc. $27.7706/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946251 CMS
Tris Pharma Inc $19.9306/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059382719 CMS
AbbVie Inc. $26.9606/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999782297 CMS
Teva Pharmaceuticals USA, Inc. $20.4106/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056828543 CMS
IDORSIA PHARMACEUTICALS US INC $22.5505/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038246061 CMS
Neos Therapeutics, LP $13.5905/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984525775 CMS
AbbVie Inc. $26.7405/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999782289 CMS
ITI, Inc. $17.5005/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040750569 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,773.33 11
PY2020 $65.09 3
PY2021 $268.69 10
PY2022 $389.28 8
PY2023 $1,820.04 73
PY2024 $683.61 29
PY2025 $717.46 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,698,890.20 111
PY2024 Principal investigator $3,248,583.50 103
PY2023 Recipient $1,039.86 1
PY2023 Principal investigator $1,084,081.62 189
PY2022 Recipient $1,428.00 1
PY2022 Principal investigator $532,395.28 190
PY2021 Recipient $1,678.03 1
PY2021 Principal investigator $1,711,588.07 233
PY2020 Principal investigator $1,081,919.61 115
PY2019 Principal investigator $698,002.09 160

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

190 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 12/29/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306939
Principal investigator 1 Incyte Corporation $7,188.36 12/28/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040876425
Principal investigator 1 Roche Diagnostics Operations, Inc. $1,260.00 12/21/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1051511419
Principal investigator 1 Roche Diagnostics Operations, Inc. $10,000.00 12/12/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1051510943
Principal investigator 1 Sumitomo Pharma America, Inc. $170.00 12/08/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306859
Principal investigator 1 Sumitomo Pharma America, Inc. $300.00 12/08/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306869
Principal investigator 1 Sumitomo Pharma America, Inc. $525.00 12/08/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306879
Principal investigator 1 Roche Diagnostics Operations, Inc. $2,992.29 12/07/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1051510245
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 11/30/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306929
Principal investigator 1 Sumitomo Pharma America, Inc. $85.00 11/27/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306837
Principal investigator 1 Sumitomo Pharma America, Inc. $315.00 11/27/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306847
Principal investigator 1 Roche Diagnostics Operations, Inc. $1,260.00 11/21/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1051511207
Principal investigator 1 Sumitomo Pharma America, Inc. $678.90 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306719
Principal investigator 1 Sumitomo Pharma America, Inc. $3,030.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306731
Principal investigator 1 Sumitomo Pharma America, Inc. $3,030.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306741
Principal investigator 1 Sumitomo Pharma America, Inc. $3,262.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306751
Principal investigator 1 Sumitomo Pharma America, Inc. $3,262.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306761
Principal investigator 1 Sumitomo Pharma America, Inc. $4,073.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306771
Principal investigator 1 Sumitomo Pharma America, Inc. $4,073.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306783
Principal investigator 1 Sumitomo Pharma America, Inc. $4,073.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306793
Principal investigator 1 Sumitomo Pharma America, Inc. $6,149.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306803
Principal investigator 1 Sumitomo Pharma America, Inc. $6,520.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306815
Principal investigator 1 Sumitomo Pharma America, Inc. $6,520.00 11/15/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306827
Principal investigator 1 Incyte Corporation $29.28 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961897
Principal investigator 1 Incyte Corporation $43.92 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961911
Principal investigator 1 Incyte Corporation $29.28 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961923
Principal investigator 1 Incyte Corporation $29.28 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961937
Principal investigator 1 Incyte Corporation $29.28 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961949
Principal investigator 1 Incyte Corporation $43.92 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961961
Principal investigator 1 Incyte Corporation $43.92 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961971
Principal investigator 1 Incyte Corporation $43.92 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961983
Principal investigator 1 Incyte Corporation $43.92 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961997
Principal investigator 1 Incyte Corporation $43.92 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040962007
Principal investigator 1 Incyte Corporation $43.92 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040962021
Principal investigator 1 Incyte Corporation $43.92 11/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040962033
Principal investigator 1 Sumitomo Pharma America, Inc. $82.92 11/02/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307163
Principal investigator 1 Sumitomo Pharma America, Inc. $168.50 11/02/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307175
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 10/31/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306919
Principal investigator 1 Sumitomo Pharma America, Inc. $105.00 10/18/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306661
Principal investigator 1 Sumitomo Pharma America, Inc. $168.00 10/18/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306671
Principal investigator 1 Sumitomo Pharma America, Inc. $204.00 10/18/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306681
Principal investigator 1 Sumitomo Pharma America, Inc. $212.00 10/18/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306689
Principal investigator 1 Sumitomo Pharma America, Inc. $280.00 10/18/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306699
Principal investigator 1 Sumitomo Pharma America, Inc. $882.00 10/18/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306709
Principal investigator 1 Sumitomo Pharma America, Inc. $63.34 10/15/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306971
Principal investigator 1 Sumitomo Pharma America, Inc. $2,891.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306439
Principal investigator 1 Sumitomo Pharma America, Inc. $2,891.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306451
Principal investigator 1 Sumitomo Pharma America, Inc. $2,891.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306461
Principal investigator 1 Sumitomo Pharma America, Inc. $3,030.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306471
Principal investigator 1 Sumitomo Pharma America, Inc. $3,030.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306483
Principal investigator 1 Sumitomo Pharma America, Inc. $3,262.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306491
Principal investigator 1 Sumitomo Pharma America, Inc. $4,073.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306503
Principal investigator 1 Sumitomo Pharma America, Inc. $4,420.40 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306513
Principal investigator 1 Sumitomo Pharma America, Inc. $6,149.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306525
Principal investigator 1 Sumitomo Pharma America, Inc. $6,149.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306535
Principal investigator 1 Sumitomo Pharma America, Inc. $6,149.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306545
Principal investigator 1 Sumitomo Pharma America, Inc. $6,149.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306557
Principal investigator 1 Sumitomo Pharma America, Inc. $6,520.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306567
Principal investigator 1 Sumitomo Pharma America, Inc. $6,520.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306577
Principal investigator 1 Sumitomo Pharma America, Inc. $6,520.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306587
Principal investigator 1 Sumitomo Pharma America, Inc. $6,520.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306599
Principal investigator 1 Sumitomo Pharma America, Inc. $6,520.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306611
Principal investigator 1 Sumitomo Pharma America, Inc. $11,833.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306621
Principal investigator 1 Sumitomo Pharma America, Inc. $11,833.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306631
Principal investigator 1 Sumitomo Pharma America, Inc. $11,833.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306641
Principal investigator 1 Sumitomo Pharma America, Inc. $11,833.00 10/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306651
Principal investigator 1 Sumitomo Pharma America, Inc. $15.84 10/11/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306961
Principal investigator 1 Sumitomo Pharma America, Inc. $1,400.00 10/04/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306429
Principal investigator 1 Roche Diagnostics Operations, Inc. $22.67 10/03/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1051510985
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 10/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307131
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 10/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307143
Principal investigator 1 Sumitomo Pharma America, Inc. $82.92 10/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307153
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 09/29/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306909
Principal investigator 1 Sumitomo Pharma America, Inc. $105.00 09/20/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306363
Principal investigator 1 Sumitomo Pharma America, Inc. $255.00 09/20/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306375
Principal investigator 1 Sumitomo Pharma America, Inc. $716.00 09/20/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306385
Principal investigator 1 Sumitomo Pharma America, Inc. $1,250.00 09/20/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306399
Principal investigator 1 Sumitomo Pharma America, Inc. $3,150.00 09/20/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306409
Principal investigator 1 Sumitomo Pharma America, Inc. $3,360.00 09/20/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306419
Principal investigator 1 Sumitomo Pharma America, Inc. $55,350.80 09/13/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306353
Principal investigator 1 Sumitomo Pharma America, Inc. $15.84 09/12/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306949
Principal investigator 1 Sumitomo Pharma America, Inc. $15.62 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307041
Principal investigator 1 Sumitomo Pharma America, Inc. $23.16 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307051
Principal investigator 1 Sumitomo Pharma America, Inc. $30.54 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307061
Principal investigator 1 Sumitomo Pharma America, Inc. $33.84 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307071
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307081
Principal investigator 1 Sumitomo Pharma America, Inc. $50.90 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307091
Principal investigator 1 Sumitomo Pharma America, Inc. $96.74 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307101
Principal investigator 1 Sumitomo Pharma America, Inc. $110.56 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307111
Principal investigator 1 Sumitomo Pharma America, Inc. $168.50 09/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307121
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 08/31/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306899
Principal investigator 1 Sumitomo Pharma America, Inc. $425.00 08/23/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306333
Principal investigator 1 Sumitomo Pharma America, Inc. $504.00 08/23/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306343
Principal investigator 1 Sumitomo Pharma America, Inc. $1,616.00 08/14/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306309
Principal investigator 1 Sumitomo Pharma America, Inc. $85,453.45 08/14/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306321
Principal investigator 1 Sumitomo Pharma America, Inc. $10.18 08/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306981
Principal investigator 1 Sumitomo Pharma America, Inc. $27.64 08/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306991
Principal investigator 1 Sumitomo Pharma America, Inc. $46.32 08/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307001
Principal investigator 1 Sumitomo Pharma America, Inc. $50.90 08/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307011
Principal investigator 1 Sumitomo Pharma America, Inc. $55.28 08/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307021
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 08/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030307031
Principal investigator 1 Sumitomo Pharma America, Inc. $5.00 08/02/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306299
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 07/31/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306889
Principal investigator 1 Roche Diagnostics Operations, Inc. $22.67 07/26/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1051509807
Principal investigator 1 PFIZER INC. $1,692.90 07/22/2023 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046241067
Principal investigator 1 Sumitomo Pharma America, Inc. $47,022.15 07/12/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030306289
Principal investigator 1 Incyte Corporation $20.42 07/05/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961771
Principal investigator 1 Incyte Corporation $37.53 07/05/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961783
Principal investigator 1 Incyte Corporation $171.25 07/05/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961795
Principal investigator 1 Incyte Corporation $175.40 07/05/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961807
Principal investigator 1 Incyte Corporation $0.33 07/05/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040961823
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 06/30/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337813
Principal investigator 1 Sumitomo Pharma America, Inc. $770.00 06/26/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337781
Principal investigator 1 Incyte Corporation $4,359.00 06/22/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040875993
Principal investigator 1 Incyte Corporation $3,098.20 06/16/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 1040875919
Principal investigator 1 Sumitomo Pharma America, Inc. $29,941.15 06/09/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337775
Principal investigator 1 Incyte Corporation $3,303.00 06/08/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040875981
Principal investigator 1 Sumitomo Pharma America, Inc. $40.72 06/01/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337837
Principal investigator 1 Sumitomo Pharma America, Inc. $50.90 06/01/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337843
Principal investigator 1 Sumitomo Pharma America, Inc. $55.28 06/01/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337851
Principal investigator 1 Sumitomo Pharma America, Inc. $55.28 06/01/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337857
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 05/31/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337807
Principal investigator 1 Eli Lilly and Company $49,242.00 05/30/2023 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038066475
Principal investigator 1 Sumitomo Pharma America, Inc. $750.00 05/12/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337751
Principal investigator 1 Sumitomo Pharma America, Inc. $1,250.00 05/12/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337757
Principal investigator 1 Sumitomo Pharma America, Inc. $1,997.00 05/12/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337763
Principal investigator 1 Sumitomo Pharma America, Inc. $37,420.50 05/12/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337769
Principal investigator 1 Sumitomo Pharma America, Inc. $975.00 05/08/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337727
Principal investigator 1 Sumitomo Pharma America, Inc. $1,600.00 05/08/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337733
Principal investigator 1 Sumitomo Pharma America, Inc. $3,000.00 05/08/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337739
Principal investigator 1 Sumitomo Pharma America, Inc. $14,438.00 05/08/2023 Non-covered Recipient Entity
K2 Medical Research Tampa LLC
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337745
Principal investigator 1 Incyte Corporation $47,947.58 05/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040875969
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 05/03/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337831
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 04/28/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337801
Principal investigator 1 Eli Lilly and Company $349,110.00 04/24/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1038104865
Principal investigator 1 PFIZER INC. $1,692.90 04/22/2023 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046022337
Principal investigator 1 Incyte Corporation $803.00 04/06/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040875957
Principal investigator 1 Sumitomo Pharma America, Inc. $4.80 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337863
Principal investigator 1 Sumitomo Pharma America, Inc. $6.60 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337869
Principal investigator 1 Sumitomo Pharma America, Inc. $10.18 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337877
Principal investigator 1 Sumitomo Pharma America, Inc. $10.18 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337883
Principal investigator 1 Sumitomo Pharma America, Inc. $12.00 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337889
Principal investigator 1 Sumitomo Pharma America, Inc. $13.82 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337895
Principal investigator 1 Sumitomo Pharma America, Inc. $16.84 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337901
Principal investigator 1 Sumitomo Pharma America, Inc. $23.16 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337907
Principal investigator 1 Sumitomo Pharma America, Inc. $27.64 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337913
Principal investigator 1 Sumitomo Pharma America, Inc. $27.64 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337919
Principal investigator 1 Sumitomo Pharma America, Inc. $33.84 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337925
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337933
Principal investigator 1 Sumitomo Pharma America, Inc. $78.10 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337939
Principal investigator 1 Sumitomo Pharma America, Inc. $337.00 04/05/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337945
Principal investigator 1 ABBVIE INC. $8,910.00 04/04/2023 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998376257
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 03/31/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337795
Principal investigator 1 Incyte Corporation $13,256.35 03/29/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040876053
Principal investigator 1 Amgen Inc. $37,500.00 03/24/2023 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH
P3 AD Adult Combo TCS No dispute reported 06/30/2026 1029653757
Principal investigator 1 PFIZER INC. $3,311.65 03/24/2023 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046283397
Principal investigator 1 Eli Lilly and Company $1,108.90 03/16/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1038104877
Principal investigator 1 Incyte Corporation $1,125.00 03/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040876041
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 02/28/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337789
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $16,046.54 02/15/2023 Non-covered Recipient Entity
Olympian Clinical Research
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1027488747
Principal investigator 1 Sumitomo Pharma America, Inc. $25.00 02/12/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337819
Principal investigator 1 Sumitomo Pharma America, Inc. $95.01 02/12/2023 Non-covered Recipient Entity
K2 Medical Research
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030337825
Principal investigator 1 Incyte Corporation $360.00 02/09/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040876029
Recipient Eli Lilly and Company $1,039.86 02/08/2023 Covered Recipient Physician A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038063395
Principal investigator 1 Eli Lilly and Company $15,933.73 02/02/2023 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1038066469
Principal investigator 1 Incyte Corporation $270.00 02/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040875943
Principal investigator 1 Incyte Corporation $2,304.00 02/02/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040876017
Principal investigator 1 Incyte Corporation $24.39 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799789
Principal investigator 1 Incyte Corporation $71.47 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799801
Principal investigator 1 Incyte Corporation $50.04 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799817
Principal investigator 1 Incyte Corporation $65.00 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799833
Principal investigator 1 Incyte Corporation $1.08 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799865
Principal investigator 1 Incyte Corporation $1.10 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799891
Principal investigator 1 Incyte Corporation $75.54 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799951
Principal investigator 1 Incyte Corporation $65.00 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799967
Principal investigator 1 Incyte Corporation $6,318.80 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 1040875906
Principal investigator 1 Incyte Corporation $1,510.00 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040875931
Principal investigator 1 Incyte Corporation $1,723.95 02/01/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040876005
Principal investigator 1 PFIZER INC. $1,922.40 01/21/2023 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046350689
Principal investigator 1 Incyte Corporation $7,237.00 01/18/2023 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040939947
Principal investigator 1 ABBVIE INC. $2,878.75 01/11/2023 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998365323
Principal investigator 1 PFIZER INC. $1,922.40 01/06/2023 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046350703
Principal investigator 1 Incyte Corporation $2.16 01/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799849
Principal investigator 1 Incyte Corporation $1.43 01/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799877
Principal investigator 1 Incyte Corporation $43.92 01/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799909
Principal investigator 1 Incyte Corporation $50.36 01/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799919
Principal investigator 1 Incyte Corporation $100.72 01/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799935
Principal investigator 1 Incyte Corporation $43.92 01/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799983
Principal investigator 1 Incyte Corporation $43.92 01/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040799999
Principal investigator 1 Incyte Corporation $43.92 01/03/2023 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040800017